Drugs / Bacillus subtilis

Trials 4 · a red edge is where a trial was stopped

20112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 22 trials
Phase 2 NCT05993247 Aug 2023 → Aug 2025 osteoarthritis Jae Myung Park Unknown No outcome recorded
Phase 2 NCT01505777 May 2011 → Jun 2012 irritable bowel syndrome Hanmi Pharmaceutical Company Limited Completed No outcome recorded
Phase not applicable2 trials
NCT05239923 Aug → Nov 2021 pneumonia DreamTec Research Limited Completed No outcome recorded
NCT05057923 Jul → Oct 2021 pneumonia DreamTec Research Limited Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT04074421 Comparator May 2020 → Jun 2022 irritable bowel syndrome Second Affiliated Hospital, School of Medicine, Zhejiang University Unknown No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as Bacillus Subtilis “Two hundred and eighty-five IBS patients were randomly assigned to either a combination of probiotics (Bacillus subtilis and Streptococcus faecium) and mosapride at one of four...” PMID 25809913 Mar 2015
4

“Probiotics combination capsule (Bacillus Subtilis 150 mg /Clostridium Burtyricum Toa 150 mg /Saccharomyces Boulardii 113 mg) per oral, three times a day, for 8 weeks” NCT05993247

“probiotic formula Bacillus subtilis and Enterococcus faecium” NCT04074421

NCT05057923

NCT05239923

Modality Vaccine “The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores” NCT05057923
Route Oral “The engineered Bacillus subtilis will be further studied in a human trials through oral administration to test its safety and the immune effect resulted in human bodys.” NCT05057923